Back

Secondary prevention in 2030: will antiplatelets or anticoagulants prevail?

2 September 2019 (12:12 - 12:30)
Organised by:
Congress Presentation Part of: Antithrombotic therapy for coronary artery disease: opportunities and challenges Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

3 More presentations in this session

Presentation thumbnail
State of the Art - New options in antithrombotic therapy for coronary artery disease
Professor K. Newby (Durham, US)
Slides Video
Presentation thumbnail
Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial
Assistant Professor K. Rizas (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry.
Doctor E. Sorbets (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy for coronary artery disease: opportunities and challenges

The Event

Event poster

ESC Congress 2019

2 September 2019 12:12 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources